Spatial heterogeneity of MRI response to first-line hormonal therapy to predict progression-free survival in metastatic breast cancer.

被引：0
|
作者：
Kosmin, Michael
Makris, Andreas
Sokhi, Heminder
Thijssen, Toon
Padhani, Anwar R.
机构：
[1] Mt Vernon Canc Ctr, Northwood, Middx, England
[2] Acad Oncol Unit, Pinner, England
[3] Paul Strickland Scanner Ctr, Northwood, Middx, England
[4] Paul Strickland Scanner Ctr, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e12544
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12544
引用
收藏
页数：6
相关论文
共 50 条
  • [21] DESCRIPTIVE STUDY OF METASTATIC BREAST CANCER PATIENTS WITH LONG-TERM PROGRESSION-FREE SURVIVAL DURING FIRST-LINE HORMONE THERAPY: EXPERIENCE FROM A SINGLE CANCER CENTER
    Illarramendi, Jose Juan
    Salgado, Esteban
    Lainez, Nuria
    Vicente, Francisco
    Cordoba, Alicia
    Vera, Ruth
    BREAST, 2011, 20 : S42 - S43
  • [22] Significantly Longer Progression-Free Survival With nab-Paclitaxel Compared With Docetaxel As First-Line Therapy for Metastatic Breast Cancer (vol 27, pg 3611, 2009)
    Gradishar
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (19) : 2739 - 2739
  • [23] Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer
    Bartlett, Cynthia Huang
    Mardekian, Jack
    Cotter, Matthew James
    Huang, Xin
    Zhang, Zhe
    Parrinello, Christina M.
    Bourla, Ariel Bulua
    PLOS ONE, 2020, 15 (04):
  • [24] Tesetaxel, an Oral Taxane, as First-Line Therapy for Women with Metastatic Breast Cancer.
    Schwartzberg, L.
    Rubin, P.
    Patnaik, A.
    Itri, L.
    Olson, A. L.
    Seidman, A. D.
    CANCER RESEARCH, 2011, 71
  • [25] PROGRESSION-FREE SURVIVAL AND POSTPROGRESSION SURVIVAL IN PATIENTS WITH ADVANCED GASTRIC CANCER TREATED WITH FIRST-LINE CHEMOTHERAPY
    Shitara, K.
    Matsuo, K.
    Muro, K.
    Ohtsu, A.
    ANNALS OF ONCOLOGY, 2012, 23 : 232 - 232
  • [26] Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy
    Shitara, Kohei
    Matsuo, Keitaro
    Muro, Kei
    Doi, Toshihiko
    Ohtsu, Atsushi
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2013, 139 (08) : 1383 - 1389
  • [27] Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy
    Kohei Shitara
    Keitaro Matsuo
    Kei Muro
    Toshihiko Doi
    Atsushi Ohtsu
    Journal of Cancer Research and Clinical Oncology, 2013, 139 : 1383 - 1389
  • [28] Chronological Trends in Progression-Free, Overall, and Post-Progression Survival in First-Line Therapy for Advanced NSCLC
    Rutkowski, Jacek
    Saad, Everardo D.
    Burzykowski, Tomasz
    Buyse, Marc
    Jassem, Jacek
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (09) : 1619 - 1627
  • [29] Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
    Beauchemin, Catherine
    Cooper, Dan
    Lapierre, Marie-Eve
    Yelle, Louise
    Lachaine, Jean
    ONCOTARGETS AND THERAPY, 2014, 7 : 1101 - 1110
  • [30] First-Line Maintenance With Erlotinib/Bevacizumab Improves Progression-Free Survival in Advanced Lung Cancer
    不详
    ONCOLOGY-NEW YORK, 2009, 23 (02): : 182 - +
12345